Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tegoprazan ± Mucosta for ulcer healing and prevention of gastrointestinal bleeding after endoscopic submucosal dissection
KCT0007063Phase 4Not yet recruiting
- Sponsor
- Korea Otsuka Pharmaceutical
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of tegoprazan, rebamipide in gastric ulcer, gastrointestinal bleeding, gastric adenoma, gastric cancer (GC), sponsored by Korea Otsuka Pharmaceutical. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
tegoprazanrebamipide
03
Conditions
gastric ulcergastrointestinal bleedinggastric adenomagastric cancer (GC)
Beyond the preview
Go deeper on KCT0007063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0007063.